米非司酮在耐药性卵巢癌治疗中的研究进展

Research Progress of Mifepristone in Drug-resistance Ovarian Cancer

米非司酮(代号RU486)是一种作用于受体水平的孕激素拮抗剂,兼有抗糖皮质激素的作用,临床上主要用于终止早孕、紧急避孕和引产等。利用其抗孕激素活性治疗子宫肌瘤、子宫内膜异位症、异位妊娠等也获得成功。研究发现,米非司酮可抑制卵巢癌上皮细胞的生长,对于耐药性卵巢癌具有一定的疗效。现对米非司酮治疗耐药性卵巢癌的作用机制、体内体外的研究进展予以综述。

Mifepristone（RU486）is a kind of antagonist acting on progesterone receptor level,which aslso function as anti-glucocorticoid.Mifepristone are mainly used to terminate the pregnancy,emergency contraception and induced abortion in clinical.In recent years,the use of its anti-progesterone activity in the treatment of uterine fibroids,endometriosis,ectopic pregnancy also succeed.Recent studies have found that mifepristone can inhere the growth of ovarian cancer epithelial cells,and has certain curative effect for drug-resistant ovarian cancer.Here is to make a review on the mechanism,in vivo and ex vivo research progress of mifepristone in the treatment of drug-resistant ovarian cancer.